First Light Asset Management LLC Raises Position in ADMA Biologics Inc $ADMA

First Light Asset Management LLC increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 12.3% during the third quarter, HoldingsChannel reports. The firm owned 1,069,233 shares of the biotechnology company’s stock after acquiring an additional 117,137 shares during the period. ADMA Biologics comprises approximately 1.5% of First Light Asset Management LLC’s portfolio, making the stock its 25th biggest holding. First Light Asset Management LLC’s holdings in ADMA Biologics were worth $15,675,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. State Street Corp grew its holdings in ADMA Biologics by 5.6% during the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock valued at $219,950,000 after purchasing an additional 637,727 shares during the period. Geode Capital Management LLC increased its position in ADMA Biologics by 4.3% in the second quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock worth $107,691,000 after buying an additional 245,309 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of ADMA Biologics in the third quarter valued at $74,866,000. Dimensional Fund Advisors LP raised its stake in shares of ADMA Biologics by 0.7% in the third quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock valued at $70,343,000 after buying an additional 35,199 shares during the period. Finally, American Century Companies Inc. lifted its position in shares of ADMA Biologics by 1.8% during the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after buying an additional 84,934 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.1%

NASDAQ:ADMA opened at $15.15 on Monday. ADMA Biologics Inc has a 1 year low of $13.76 and a 1 year high of $25.67. The stock’s fifty day moving average price is $16.63 and its two-hundred day moving average price is $16.70. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The company has a market cap of $3.61 billion, a P/E ratio of 25.25 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same period in the previous year, the business earned $0.46 earnings per share. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. As a group, analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several research reports. Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $32.00.

Insider Activity

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms purchased 7,000 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were bought at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.70% of the stock is owned by company insiders.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.